Orchid Pharma, which is seeing a turnaround under its new promoter Dhanuka Group, aspires to be a fully integrated powerhouse of cephalosporin antibiotics, the company’s top executive said.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Orchid Pharma Ltd., a vertically integrated pharmaceutical company spanning the entire pharmaceutical value chain from discovery to delivery, announced the successful completion of a surprise US Food ...

Orchid Pharma Limited recently announced the launch of its new drug – Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital ...

One pharma stock that has delivered a whopping return of nearly 7,000 per cent return is Orchid Chemicals & Pharmaceuticals Limited. According to exchange data, Orchid Pharma share has rallied ...

Orchid Pharma Limited, is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in development, manufacture and marketing of diverse bulk actives ...

of Orchid Pharma Limited for Quarter- II and Half Year ended on September 30, 2024 of Financial Year 2024-25 ...

Orchid AMS Division Impact: EBITDA drag of about INR 6 Crores on a 9-month basis. Orchid Pharma Ltd (BOM:524372) reported a 15% growth in total income for the first nine months of FY25, reaching ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...